<DOC>
	<DOCNO>NCT00057447</DOCNO>
	<brief_summary>Evaluate safety efficacy dose schedule subcutaneous interferon gamma-1b ( IFN g-1b ) administer 3 time per week Rituximab 4 week , patient progressive relapse low-grade Non-Hodgkin 's Lymphoma ( NHL ) International study sit Czech Republic Poland</brief_summary>
	<brief_title>Safety Interferon Gamma-1b With Rituximab Non-Hodgkin 's Lymphoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria>Relapsed progressive lowgrade/follicular NHL candidate rituximab therapy Patients therapy include CHOP radiation Previous therapy must conclude 30 day prior enrollment Demonstrable CD20positive tumor population lymph node bone marrow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>lymphoma</keyword>
</DOC>